Core Viewpoint - The article emphasizes the importance of the "self-care" concept in the skincare industry, highlighting how brands like Keli Jin are redefining anti-aging narratives by integrating cultural philosophies and emotional connections into their products and experiences [4][10][22]. Group 1: Brand Activities and Philosophy - Keli Jin's event "My 'Reorganization' Energy" in Chengdu reflects a shift towards creating a gentle space for urban dwellers, focusing on self-awareness and emotional needs through skincare [2][4]. - The brand utilizes Eastern wellness philosophies, such as "regulating energy, following trends, and maintaining harmony," to connect skincare with personal well-being [2][7]. - The event featured activities like morning exercises and DIY scent bags, which engage multiple senses and promote a holistic approach to skincare [6][8]. Group 2: Emotional Connection and Consumer Engagement - The concept of "self-care" has evolved into a crucial channel for brands to establish deeper relationships with younger consumers, who seek products that resonate with their lifestyles and emotional needs [4][10]. - Keli Jin aims to transition from a focus on product functionality to building emotional connections, making "self-care" a core element of its brand identity [4][10][12]. Group 3: Technological Integration and Product Development - Keli Jin leverages over 20 years of research in recombinant collagen technology, holding 167 patents and applications, positioning itself as a leader in this field [12][22]. - The brand's core ingredient, C5HA recombinant collagen, is scientifically formulated to enhance skin absorption and promote collagen production, addressing both efficacy and consumer trust [12][14]. - Keli Jin's product matrix includes a range of items designed for both morning and night use, catering to the growing demand for "time-specific care" and "certain efficacy" among consumers [16][18]. Group 4: Market Trends and Brand Strategy - The skincare industry is witnessing a structural shift where emotional resonance and understanding consumer needs are becoming as important as product efficacy [19][22]. - Keli Jin's dual strategy of combining "soft narrative" with "hard technology" allows it to build a brand model that is both scientifically grounded and emotionally engaging [22][30]. - The brand's approach to anti-aging is reframed from a battle against time to a gentle reorganization of one's state, aligning with modern consumer desires for self-acceptance and emotional well-being [29][30].

Core Viewpoint - The ongoing debate regarding "recombinant collagen" has raised significant industry and market attention, with the company emphasizing the need to correct misleading perceptions in the capital market that deviate from scientific and industrial fundamentals [1][2]. Group 1: Company Position on Recombinant Collagen - The company argues that recombinant collagen is a minor branch of collagen research and industrial transformation, with the main advancements in protein research being led by life science institutions and pharmaceutical companies, not cosmetic firms [1][2]. - The company highlights that there is currently no international approval for medical devices based on recombinant collagen, indicating the need for longer observation periods in this field [2]. - The company asserts that the growth of its hyaluronic acid business remains stable, with an annual growth rate exceeding 10%, while the recombinant collagen market lacks a mature international market comparable to hyaluronic acid [3][4]. Group 2: Market Dynamics and Performance - The company clarifies that its performance adjustments are not solely due to the rise of recombinant collagen, as its hyaluronic acid business continues to grow, particularly in the pharmaceutical-grade and overseas export segments, which have seen over 20% growth [3][4]. - The decline in overall performance is attributed to a downturn in consumer goods and one-time asset impairment losses, rather than the emergence of recombinant collagen as a competitive force [4]. - The company emphasizes that the concept of "recombinant collagen" is often misrepresented, as it does not meet the academic standards required for biological functionality [5][6]. Group 3: Industry Ecosystem and Communication - The company stresses the importance of establishing a credible foundation for domestic brands, which should not rely on the misuse of academic terms and concepts that mislead consumers [7]. - The company calls for a collaborative effort among industry participants, regulatory bodies, and media to enhance understanding and improve the overall ecosystem, ensuring that scientific and industrial developments are accurately represented [9]. - The company plans to strengthen professional communication with the capital market, recognizing the need for better understanding of the biological sciences among analysts and investors [8].

Core Viewpoint - The ongoing public dispute between two major players in the beauty industry, Huaxi Biological and Juzhi Biological, has escalated into a fierce battle over allegations of fraud and market manipulation, significantly impacting their market positions and stock prices [1][4][34]. Group 1: Background and Timeline - The conflict began on May 17 when Huaxi Biological publicly criticized several brokerage reports that favored Juzhi Biological's products, suggesting they misled the market [5][6]. - On May 24, beauty influencer Hao Yu accused Juzhi Biological of fraud regarding its "collagen stick" product, claiming the actual collagen content was only 0.0177%, far below the labeled 0.1% [16][17]. - Following these allegations, Juzhi Biological issued a rebuttal, presenting an internal quality inspection report to counter the fraud claims [18][19]. Group 2: Market Impact - Since the dispute began, Huaxi Biological's stock price has increased by approximately 6.8%, while Juzhi Biological's stock has seen a cumulative decline of 25.20%, resulting in a market value loss of over 16 billion HKD [34]. - The consumer market has also reacted, with Juzhi Biological's product ranking dropping significantly on e-commerce platforms, indicating a shift in consumer perception [36]. Group 3: Industry Dynamics - The conflict highlights a broader competition between two factions in the beauty industry: the hyaluronic acid camp represented by Huaxi Biological and the recombinant collagen camp led by Juzhi Biological [39]. - The rise of recombinant collagen products has been attributed to a lack of standardized regulations and testing methods, allowing companies like Juzhi Biological to capitalize on marketing without stringent scientific backing [41]. - In contrast, Huaxi Biological has faced significant challenges, with its market value plummeting from 140 billion to 26.1 billion, while Juzhi Biological's market capitalization has surged by 230% since its IPO [37].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating potential growth opportunities in the sector [2]. Core Insights - The domestic brands showcased strong performance on Douyin, with Feicui achieving a GMV of nearly 500 million, marking a new high for the year [6][12]. - The cosmetics and medical beauty sector performed in line with the market, with the Shenwan Beauty Care Index rising by 1.6% from May 30 to June 6, 2025 [6][7]. - International cosmetic companies are experiencing a decline or slowdown in growth, with L'Oréal's Q1 2025 revenue growth at 4.4%, and Estée Lauder facing a significant drop in revenue and operating profit [13][15][16]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index increased by 1.6%, while the Shenwan Cosmetics Index rose by 0.7%, slightly underperforming the Shenwan A Index [6][7]. - Domestic brands like Marubi and Yilian have shown over 50% growth in skincare, while color cosmetics brands like Caitang and Maogeping achieved over 70% growth [12]. Key Developments - Leping Medical's "童颜针" (Youthful Needle) received approval, marking a competitive entry into the domestic market for facial fillers [26]. - Furuida's synthetic royal jelly acid (10-HDA) has achieved industrialization, providing a high-purity ingredient for anti-aging products [27]. Investment Recommendations - Recommended stocks include: 1. Upstream companies with strong R&D capabilities and profitability, such as Aimeike [17]. 2. Brands benefiting from Douyin traffic, like Marubi [17]. 3. Companies with strong product innovation and cost-effectiveness, such as Runben and Furuida [17]. - Suggested to pay attention to Shanghai Jahwa, Betaini, Huaxi Biological, and Water Sheep [17]. Market Trends - The cosmetics market in China is projected to grow, with a retail sales increase of 7.2% in April 2025, indicating a recovery in consumer demand [23][25]. - The market share of domestic brands in the skincare segment has improved significantly, with domestic brands occupying five out of the top ten positions in market share [36][37].

Core Viewpoint - The controversy surrounding the product "Kefumei" from Juzhi Biotechnology has escalated into a significant public debate over the authenticity of its key ingredient, recombinant collagen, leading to a broader discussion about ingredient marketing in the domestic beauty industry [1][3][4]. Group 1: Incident Overview - The dispute began on May 24 when beauty blogger "Dr. Big Mouth" Hao Yu accused Juzhi Biotechnology of falsely advertising the collagen content in its "Kefumei" product, claiming the actual amount was only 0.0177%, while it should be above 0.1% to comply with regulations [3][4]. - Juzhi Biotechnology responded with its own testing results, asserting compliance, but the blogger continued to question the validity of these results, leading to a back-and-forth that has lasted 12 days [3][4]. - The incident has resulted in a significant market impact, with Juzhi Biotechnology's market value dropping by over 20%, amounting to nearly 20 billion HKD [4]. Group 2: Industry Context - The beauty industry in China has increasingly relied on ingredient marketing, with companies like Huaxi Biotechnology leveraging popular ingredients like hyaluronic acid to drive sales [5][6]. - Juzhi Biotechnology's revenue for 2024 is projected to reach 5.54 billion RMB, a 57.2% increase year-on-year, with the "Kefumei" brand contributing over 80% of this revenue [4][6]. - The reliance on e-commerce channels is evident, with direct-to-consumer (DTC) sales accounting for 71.6% of Juzhi's total revenue, up from 65.2% the previous year [6]. Group 3: Market Dynamics - The ongoing debate highlights a "arms race" in ingredient marketing within the domestic beauty sector, where companies must continuously innovate and promote new ingredients to attract consumer interest and investment [1][5]. - The lack of industry standards for new ingredients like recombinant collagen complicates the situation, as companies can interpret and market these ingredients in ways that may not align with consumer expectations [10][11]. - The competitive landscape is further complicated by the contrasting fortunes of companies like Juzhi Biotechnology, which has seen its valuation rise, versus Huaxi Biotechnology, which has experienced declining revenues and profits [8][9].

Group 1 - Jialong Co. expects its soy sauce products to be launched in the second half of the year, with progress on the business proceeding smoothly [1] - Babi Foods reports that the median order amount for stores in East China has turned positive year-on-year for April and May, with a stable closure rate [2] - Muyuan Foods announces a sales revenue of 12.258 billion yuan from commodity pigs in May, reflecting a year-on-year increase of 26.93% [3] Group 2 - Haitian Flavor Industry's board has approved the global offering of H-shares and listing on the Hong Kong Stock Exchange [4] - Wens Foodstuff Group has undergone a change in actual controllers, with a new agreement signed by ten individuals, holding a combined 11.94% of the total share capital [5] - White Elephant Foods clarifies that its "Duoban" products are larger versions of existing products and will adjust packaging to avoid consumer confusion [6] Group 3 - Juzhi Biotechnology confirms that its recombinant collagen products contain real added collagen, with testing results showing content greater than 0.1% [7][8] - *ST Renle announces that its stock will enter a delisting arrangement period starting June 13, 2025, with the last trading day expected to be July 3, 2025 [9] - The involved blogger in the "Red Underwear" case related to Pang Donglai has issued an apology video, complying with the court's judgment [10]

Core Viewpoint - The ongoing controversy surrounding the collagen content claims by Juzhi Biotechnology highlights a deeper crisis of trust within the skincare industry, exacerbated by a lack of transparency and regulatory standards [1][2][3]. Group 1: Industry Trust Issues - The dispute over ingredient authenticity has revealed significant gaps in consumer trust and industry standards, with companies often engaging in "black box" practices that obscure the true efficacy of their products [3][4]. - The skincare sector is facing a crisis where consumers are increasingly skeptical of scientific claims, demanding transparency and accountability from brands [3][10]. Group 2: Regulatory and Market Dynamics - Recent events, including a fine imposed on CSS for false advertising, illustrate the consequences of misleading marketing practices, with penalties disproportionately affecting downstream partners rather than brands [6][9]. - The market for soluble collagen and other active ingredients is experiencing explosive growth, with a reported 106.93% increase in soluble collagen registrations, indicating a shift in consumer preferences towards these components [6][9]. Group 3: Ingredient Efficacy and Marketing Practices - The industry is grappling with two main issues: the imbalance in quantifying ingredient efficacy and the use of "shadow ingredients" to mislead consumers about product value [7][8]. - Companies are often reducing the actual amounts of active ingredients to cut costs, leading to a significant disparity between product claims and actual performance, which undermines consumer trust [7][8]. Group 4: Future Opportunities and Challenges - The lack of standardized testing methods and regulatory frameworks is creating a fragmented market where companies can exploit loopholes, leading to a potential collapse of consumer confidence [10][11]. - The need for an open and transparent verification platform is critical for establishing trust and setting future industry standards, as current practices are failing to meet consumer expectations [10][11].

Core Viewpoint - The controversy surrounding the collagen products of Juzhi Biotechnology has intensified, with beauty blogger "Dr. Big Mouth" questioning the validity of the company's testing reports and the lack of transparency regarding the testing institutions involved [1][2]. Group 1: Company Response - Juzhi Biotechnology claims that multiple authoritative testing institutions have confirmed the presence of recombinant collagen in their products, specifically in the "Human-like Recombinant Collagen Essence" [1]. - The company asserts that the collagen content is greater than 0.1% and that the product has been sold out across various channels, countering claims of a "quiet removal" from the market [1]. Group 2: Critic's Concerns - The critic highlights four main doubts regarding the testing reports: 1. The use of different testing methods raises questions about the accuracy and consistency of results, particularly why a less precise method was used instead of a high-precision mass spectrometry method [2]. 2. The claim of 100% homology with human collagen is disputed, as the critic points out that the company's own patent indicates only 86% homology when using standard comparison methods [2]. 3. The absence of blank controls in the double biuret method testing is questioned, as it is unclear how the base components of the formula affect the results [2]. 4. The lack of names and seals from the testing institutions on the reports is criticized, suggesting that the reports lack credibility and transparency [2].

文 | 新浪财经 徐苑蕾 近几年，凭借核心护肤品牌可复美，巨子生物的业绩节节攀升， 2024 年可复美品牌贡献 45.4 亿元，营收占比达到 82% 。然而，巨子生物也多次因产品成分陷入争议，舆论风波 使得公司的品牌公信力受到严峻考验。 近日，业内两大巨头 —— 巨子生物与华熙生物因 " 重组胶原蛋白 " 真实含量问题爆发激 烈争议，从产品成分质疑升级至公开 " 商战 " 。在 618 大促的关键节点，涉事产品可复 美 " 胶原棒 "1.0 版本已在多个电商平台下架。 随着事件进一步发酵升级，背后隐藏的技术路线之争与行业标准缺失问题也浮出水面。一位 化妆品行业人士直指，巨子生物和华熙生物的"开撕"，本质是两家企业对市场份额和行业 主导权的争夺。 昨晚，巨子生物发布最新回应，并公布了多家权威检测机构的检测数据：经多个检测机构对 多批次"胶原棒"进行检测分析，确认产品中重组胶原蛋白含量均大于 0.1% 。巨子生物强 调，可复美相关产品不存在 " 虚假宣传 " 的行为。同时，可复美胶原棒 1.0 版本因售罄陆 续下架，并非网传的 " 悄悄下架 " 。 检测报告引爆争议， 国内医美行业正经历一场 " 成分风暴 " 。 ...

Core Viewpoint - The domestic medical beauty industry is experiencing a "component storm," highlighted by a fierce dispute between two major players, Giant Bio and Huaxi Bio, over the actual content of "recombinant collagen" in their products, escalating from product composition doubts to a public "business war" [2][3] Group 1: Industry Dispute - The controversy was ignited by a report from Dr. Hao Yu, which claimed that the recombinant collagen content in Giant Bio's product was only 0.0177%, significantly below the stated level of over 0.1% [3] - Giant Bio responded by asserting that the accusations were "seriously inaccurate" and provided self-test results confirming compliance with standards [3][5] - Huaxi Bio publicly supported Dr. Hao and accused Giant Bio of using online tactics to manipulate public perception, escalating the conflict [5] Group 2: Market Impact - Following the dispute, regulatory authorities in Shaanxi Province initiated an investigation, and the stock market reacted with Giant Bio's shares dropping approximately 13% while Huaxi Bio's shares rose about 9.8% [6] - The market's focus on recombinant collagen has surged, with a report indicating a compound annual growth rate of 63% from 2017 to 2022, and an expected growth rate of 42.4% from 2022 to 2027, reaching 108.3 billion [9] Group 3: Financial Performance - Despite the controversies, Giant Bio's performance remains strong, with a projected revenue of 55.39 billion in 2024, a 57% year-on-year increase, and a net profit of 20.62 billion, up 42% [11] - The brand Kefu Mei contributed 45.4 billion to revenue, accounting for 82% of total sales, but the company faces risks due to its heavy reliance on this single brand [11][14] Group 4: Industry Standards - The dispute highlights the lack of unified testing standards for recombinant collagen, leading to significant discrepancies in results from different testing institutions [10] - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen testing methods, indicating a move towards regulatory improvement [10]